Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Jordi Remon; Noemí Reguart; Edouard Auclin; Benjamin Besse

doi:10.1016/j.jtho.2019.02.031

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Jordi Remon, Noemí Reguart, Edouard Auclin, Benjamin Besse

Résultats de recherche: Contribution à un journal › !!Comment/debate

16 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	963-967
Nombre de pages	5
journal	Journal of Thoracic Oncology
Volume	14
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.jtho.2019.02.031
état	Publié - 1 juin 2019

Accès au document

10.1016/j.jtho.2019.02.031

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{09cb0163c26141c7a6bcb649ff5778f1,

title = "Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?",

author = "Jordi Remon and Noem{\'i} Reguart and Edouard Auclin and Benjamin Besse",

note = "Funding Information: Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celg{\`e}ne, Eli Lilly and Company, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD), Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest. Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celg{\`e}ne, Eli Lilly and Company, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD), Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest. Funding Information: Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb , AstraZeneca , and Roche ; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie , Amgen , AstraZeneca , Biogen , Blueprint Medicines, Bristol-Myers Squibb , Celg{\`e}ne, Eli Lilly and Company , GlaxoSmithKline , Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD) , Nektar, Onxeo, Pfizer , Pharma Mar, Sanofi , Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest. Funding Information: Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celg{\`e}ne, Eli Lilly and Company, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD), Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest.",

year = "2019",

month = jun,

day = "1",

doi = "10.1016/j.jtho.2019.02.031",

language = "English",

volume = "14",

pages = "963--967",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "6",

}

TY - JOUR

T1 - Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

T2 - A Predictive Marker of Efficacy?

AU - Remon, Jordi

AU - Reguart, Noemí

AU - Auclin, Edouard

AU - Besse, Benjamin

N1 - Funding Information: Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgène, Eli Lilly and Company, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD), Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest. Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgène, Eli Lilly and Company, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD), Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest. Funding Information: Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb , AstraZeneca , and Roche ; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie , Amgen , AstraZeneca , Biogen , Blueprint Medicines, Bristol-Myers Squibb , Celgène, Eli Lilly and Company , GlaxoSmithKline , Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD) , Nektar, Onxeo, Pfizer , Pharma Mar, Sanofi , Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest. Funding Information: Disclosure: Dr. Remon reports personal fees for serving on advisory committees of Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Bristol-Myers Squibb, and AstraZenica; reimbursement for travel expenses from Ose Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche; and speaker fees from Pfizer outside the submitted work. Dr. Reguart reports personal fees from Merck Sharp and Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, AbbVie, Ipsen AstraZeneca, Eli Lilly and Company, and Takeda and grants and personal fees from Pfizer from Novartis outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgène, Eli Lilly and Company, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp and Dohme (MSD), Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Takeda, and Tiziana Pharma outside the submitted work. The remaining author declares no conflict of interest.

PY - 2019/6/1

Y1 - 2019/6/1

UR - http://www.scopus.com/inward/record.url?scp=85064552924&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.02.031

DO - 10.1016/j.jtho.2019.02.031

M3 - Comment/debate

C2 - 31027971

AN - SCOPUS:85064552924

SN - 1556-0864

VL - 14

SP - 963

EP - 967

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 6

ER -